Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis

Journal of Women's Health

Volumn 18, Issue 10, 2009, Pages 1615-1626

  Lewiecki, E Michael ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ARZOXIFENE; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTROGEN; GESTAGEN; IBANDRONIC ACID; LASOFOXIFENE; OSPEMIFENE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; BREAST CANCER; CALCIUM INTAKE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIAL DISEASE; ENDOMETRIAL THICKENING; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FLU LIKE SYNDROME; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; LEG CRAMP; LOW DRUG DOSE; MASTALGIA; MYALGIA; NAUSEA; NONHUMAN; OSTEOPENIA; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT OUTCOME; VAGINA BLEEDING; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; VITAMIN INTAKE;

AGED; ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDOLES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PIPERIDINES; POSTMENOPAUSE; PYRROLIDINES; RALOXIFENE; RANK LIGAND; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TETRAHYDRONAPHTHALENES; THIOPHENES; VITAMIN D; WOMEN'S HEALTH;

EID: 70350440129     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2008.1086     Document Type: Review

References (153)

1. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006;13:340-367.
2. Iba K, Takada J, Hatakeyama N, et al. Underutilization of antiosteoporotic drugs by orthopedic surgeons for prevention of a secondary osteoporotic fracture. J Orthop Sci 2006;11:446-449.
3. Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: A nationwide study from Denmark. Osteoporos Int 2005;16:134-141.
4. Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 2006;99:570-575.
5. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117-1123.
6. Dennison E, Cooper C. Epidemiology of osteoporotic fractures. Horm Res 2000;54:58-63.
7. Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997;12:1761-1768.
8. Gajic-Veljanoski O, Sebaldt RJ, Davis AM, et al. Age and drug therapy are key prognostic factors for first clinical fracture in patients with primary osteoporosis. Osteoporos Int 2007;18:1091-1100.
9. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005;16(Suppl 2):S3-S7.
10. Melton LJ III, Thamer M, Ray NF, et al. Fractures attributable to osteoporosis: Report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:16-23.
11. Wainwright SA, Marshall LM, Ensrud KE, et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005;90:2787-2793.
12. Nguyen TV, Center JR, Eisman JA. Osteoporosis: Underrated, underdiagnosed and undertreated. Med J Aust 2004;180:S18-S22.
13. Delmas PD, van de Langerijt L, Watts NB, et al. Underdiagnosis of vertebral fractures is a worldwide problem: The IMPACT study. J Bone Miner Res 2005;20:557-563.
14. Kamel HK. Secondary prevention of hip fractures among the hospitalized elderly: Are we doing enough? J Clin Rheumatol 2005;11:68-71.
15. Riggs BL, Melton LJI. The worldwide problem of osteoporosis: Insights afforded by epidemiology. Bone 1995;17: 505S-511S.
16. Atik OS, Gunal I, Korkusuz F. Burden of osteoporosis. Clin Orthop Relat Res 2006;443:19-24.
17. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-323.
18. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-739.
19. Schlaich C, Minne HW, Bruckner T, et al. Reduced pulmonary function in patients with spinal osteoporotic fractures. Osteoporos Int 1998;8:261-267.
20. Silverman SL, Minshall ME, Shen W, Harper KD, Xie S. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: Results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 2001;44:2611-2619.
21. Bianchi ML, Orsini MR, Saraifoger S, Ortolani S, Radaelli G, Betti S. Quality of life in post-menopausal osteoporosis. Health Qual Life Outcomes 2005;3:78.
22. Silverman SL, Shen W, Minshall ME, Xie S, Moses KH. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and=or prevalent vertebral fracture: Results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. J Rheumatol 2007;34: 140-144.
23. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-561.
24. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ III. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001-1005.
25. World Health Organization Collaborating Centre for Metabolic Bone Diseases. FRAX- WHO Fracture Risk Assessment Tool. Available at www.shef.ac.uk=FRAX= Accessed March 1, 2008.
26. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the U.K. Osteoporos Int 2008;19:385-397.
27. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Available at www.nof.org/professionals/Clinicians- Guide.htm Accessed December 9, 2008.
28. Gronholz MJ. Prevention, diagnosis, and management of osteoporosis-related fracture: A multifactorial osteopathic approach. J Am Osteopath Assoc 2008;108:575-585.
29. Holick MF. The role of vitamin D for bone health and fracture prevention. Curr Osteoporos Rep 2006;4:96-102.
30. National Osteoporosis Foundation. Scientific statement: Updated recommendations for calcium and vitamin D intake. Available at www.nof.org/prevention/calcium-and-VitaminD.htm Accessed November 18, 2007.
31. Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990;323:878-883.
32. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-676.
33. Chapuy MC, Pamphile R, Paris E, et al. Combined calcium and vitamin D3 supplementation in elderly women: Con- firmation of reversal of secondary hyperparathyroidism and hip fracture risk: The Decalyos II study. Osteoporos Int 2002;13:257-264.
34. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-683. (Pubitemid 43247138)
35. Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): A randomised placebo-controlled trial. Lancet 2005;365:1621-1628.
36. Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005;330:1003.
37. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis. Lancet 2007;370:657-666.
38. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: A meta-analysis. JAMA 2004; 291:1999-2006.
39. Bischoff HA, Stahelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: A randomized controlled trial. J Bone Miner Res 2003;18:343-351.
40. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000;15: 1113-1118.
41. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr 2007;85:1586-1591.
42. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-4124.
43. Bobba RS, Beattie K, Parkinson B, Kumbhare D, Adachi JD. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf 2006;29:1133-1152.
44. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199.
45. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-1352.
46. Grey A, Reid IR. Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag 2006;2:77-86.
47. Chesnut CHI, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-1249.
48. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;CD004523.
49. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;CD001155.
50. FOSAMAX® (alendronate sodium) tablets and oral solution [package insert]. Whitehouse Station, NJ: Merck & Co., 2007.
51. ACTONEL® (risedronate sodium tablets) [package insert]. Cincinnati, OH: Proctor & Gamble Pharmaceuticals, 2007.
52. BONIVA® (ibandronate sodium) tablets [package insert]. Nutley, NJ: Roche Pharmaceuticals, 2006.
53. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18: 1023-1031.
54. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71: 103-111.
55. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-661.
56. Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, Haentjens P. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: Enhanced efficacy by enhanced compliance. J Intern Med 2008;264:315-332.
57. Pasion EG, Sivananthan SK, Kung AW, et al. Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. J Bone Miner Metab 2007;25:105-113.
58. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-661. (Pubitemid 34815869)
59. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54:1838-1846.
60. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
61. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995;122:9-16.
62. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA 2003;290:1729-1738.
63. Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:875-883.
64. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
65. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen=progestin Replacement Study followup (HERS II). JAMA 2002;288:49-57. (Pubitemid 34705518)
66. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen=progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66. (Pubitemid 34705519)
67. Kleerekoper M. Osteoporosis prevention and therapy: Preserving and building strength through bone quality. Osteoporos Int 2006;17:1707-1715.
68. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87: 3609-3617.
69. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 1999;282:637-645.
70. Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Anti-vertebral fracture efficacy of raloxifene: A metaanalysis. Osteoporos Int 2006;17:313-316.
71. Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ. Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J Bone Miner Res 2004; 19:1270-1275.
72. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137. (Pubitemid 44050394)
73. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
74. Mosca L, Grady D, Barrett-Connor E, et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 2009;40:147-155.
75. Bushardt RL, Turner JL, Ragucci KR, Askins DG Jr. Nonestrogen treatments for osteoporosis: An evidence-based review. JAAPA 2006;19:25-30.
76. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures study. PROOF Study Group. Am J Med 2000;109:267-276.
77. Ellerington MC, Hillard TC, Whitcroft SI, et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996;59:6-11.
78. MIACALCIN® (calcitonin-salmon) nasal spray [package insert]. Huningue, France: Novartis Pharma S.A.S., 2006.
79. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441.
80. Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528-4535.
81. FORTEO® teriparatide (rDNA origin) injection 750 mcg= 3mL [package insert]. Indianapolis, IN: Eli Lilly, 2007.
82. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703.
83. Seeman E. Preventing fractures-How good are we really? Nat Clin Pract Endocrinol Metab 2006;2:606-607.
84. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001;69:121-129.
85. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis-A 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87: 2060-2066.
86. Reginster JY, Meunier PJ. Strontium ranelate phase 2 doseranging studies: PREVOS and STRATOS studies. Osteoporos Int 2003;14 (Suppl 3):S56-S65.
87. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-2822.
88. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350: 459-468. (Pubitemid 38133766)
89. Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD. Patient adherence to osteoporosis medications: Problems, consequences and management strategies. Drugs Aging 2007;24:37-55.
90. Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006;28:1686-1694.
91. Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clin Ther 2004;26:245-256.
92. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: Finding the root of the problem. Am J Med 2006;119:S12-S17.
93. Silverman SL, Gold DT. Compliance and persistence with osteoporosis therapies. Curr Rheumatol Rep 2008;10:118-122.
94. Moro-Alvarez MJ, Diaz-Curiel M. Risedronate once monthly: A potential new regimen for the treatment of postmenopausal osteoporosis. Clin Interventions Aging 2008;3:227-232.
95. Penning-van Beest FJA, Erkens JA, Olson M, Herings RMC. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 2008;19:511-517.
96. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-1022.
97. Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 2007;23:585-594.
98. McCombs JS, Thiebaud P, Laughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-287.
99. Simpson SH, Eurich DT, Majumdar SR, et al. A metaanalysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:15.
100. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: A study in women with postmenopausal osteoporosis. Clin Ther 2006;28:236-242.
101. Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 2007;30:755-763.
102. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005;165:2414-2419.
103. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491.
104. Seeman E. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 2007;41:308-317.
105. Lewiecki EM, Lane NE. Common mistakes in the clinical use of bone mineral density testing. Nat Clin Pract Rheumatol 2008;4:667-674.
106. Camacho PM, Lopez NA. Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis. Clin Chem Lab Med 2008;46:1345-1357.
107. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-1056.
108. Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999;84: 2363-2368. (Pubitemid 30670863)
109. Fleischer AC, Wheeler JE, Yeh IT, Kravitz B, Jensen C, MacDonald B. Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. J Ultrasound Med 1999;18:503-512.
110. Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. J Clin Endocrinol Metab 2001;86:755-760.
111. Goldstein SR, Nanavati N. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 2002;187:521-527.
112. Smith K. Beecham drops idoxifene for osteoporosis. SCRIP 1999;2431:21.
113. Novo Nordisk drops levormeloxifene. SCRIP 1998;2374:18.
114. Lewiecki EM. Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of post- menopausal osteoporosis. Expert Opin Investig Drugs 2007;16:1663-1672.
115. Gruber C, Gruber D. Bazedoxifene (Wyeth). Curr Opin Investig Drugs 2004;5:1086-1093.
116. Komm BS, Lyttle CR. Developing a SERM: Stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann NY Acad Sci 2001;949:317-326.
117. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999-4008.
118. Marín F, Barbancho MC. Clinical pharmacology of selective estrogen receptor modulators (SERMs). In: Sanchez AC, Alsina JCi, Dueñas- Díez JL, eds. Selective estrogen receptor modulators. A new brand of multitarget drugs. New York: Springer, 2006:49-65.
119. Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105:1397-1404. (Pubitemid 40734275)
120. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-1934.
121. Adachi JD, Chesnut CH, Brown JP, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placeboand active-controlled clinical trial. J Bone Miner Res 2007;22:S460 [Abstract W385].
122. Archer DF, Pinkerton JV, Utian W, et al. Bazedoxifene, a selective estrogen receptor modulator: Effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women [published online ahead of print June 10, 2009]. Menopause doi:10.1097=gme. 06013e3181a818db.
123. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-year results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525-535.
124. Pinkerton JV, Archer DF, Utian WH, et al. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis [published online ahead of print June 10, 2009]. Menopause doi:10.1097=gme. 0601ze3181a816be.
125. Ke HZ, Paralkar VM, Grasser WA, et al. Effects of CP- 336,156, a new, nonsteroidal estrogen agonist=antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 1998;139:2068-2076.
126. Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 2004;145:1996-2005.
127. Wang XN, Simmons HA, Salatto CT, Cosgrove PG, Thompson DD. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats. Menopause 2006;13:609-620.
128. Lees C, Shen V, Brommage R. Effects of lasofoxifene on bone in surgically postmenopausal cynomolgus monkeys. Menopause 2007;14:97-105.
129. McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene lasofoxifene compared with raloxifene. Menopause 2006;13: 377-386.
130. Cummings SR, Eastell R, Ensrud K, et al. The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL Trial. J Bone Miner Res 2008;23:81 [Abstract 1288].
131. Eastell R, Reid DM, Vukicevic S, et al. The effects of lasofoxifene on bone turnover markers: The PEARL Trial. J Bone Miner Res 2008;23:81 [Abstract 1287].
132. Pfizer Inc. FABLYN® (lasofoxifene tartrate) 0.5mg tablets. NDA 22-242. Reproductive Health Drugs Advisory Committee Briefing Document, September 8, 2008. Available atwww .fda.gov/ohrms/dockets/ac/08/briefing/2008- 4381b102- Pfizer.pdf Accessed October 27, 2008.
133. CORAL: Comparison of raloxifene and lasofoxifene-A randomized, blinded study of these drugs and placebo on bone loss. Clinical Trials.gov Identifier: NCT00163137. Available at www.clinicaltrials.gov/ct/show/NCT00163137 ?order=3 Accessed April 24, 2008.
134. Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000;141: 809-820.
135. Komi J, Heikkinen J, Rutanen EM, Halonen K, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol 2004;18:152-158.
136. Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: A doubleblind, randomized trial. Menopause 2003;10:433-439.
137. Komi J, Lankinen KS, DeGregorio M, et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab 2006;24:314-318.
138. Deshmane V, Krishnamurthy S, Melemed AS, Peterson P, Buzdar AU. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol 2007;25:4967-4973.
139. Ma YL, Bryant HU, Zeng Q, et al. Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. J Bone Miner Res 2002;17:2256-2264.
140. Sato M, Turner CH, Wang T, Adrian MD, Rowley E, Bryant HU. LY353381.HCl: A novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 1998;287:1-7.
141. Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Selective estrogen receptor modulators for postmenopausal osteoporosis: Current state of development. Drugs Aging 2007;24:361-379.
142. U.S. National Institute of Health, National Library of Medicine. Effects of arzoxifene on bone mass and the uterus. Available at www.clinicaltrials.gov= ct2=show= NCT00085956 Accessed April 8, 2008.
143. Effects of arzoxifene on bone fractures and incidence of breast cancer. ClinicalTrials.gov Identifier: NCT00088010. Available at www.clinicaltrials.gov/ ct/show/NCT00088010 Accessed April 8, 2008.
144. Study comparing arzoxifene with raloxifene in women after menopause with osteoporosis. ClinicalTrials.gov Identifier: NCT00383422. Available at www.clinicaltrials.gov/ct/show/NCT00383422?order=5 Accessed April 24, 2008.
145. Baselga J, Llombart-Cussac A, Bellet M, et al. Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann Oncol 2003;14:1383-1390.
146. Buzdar A, O'Shaughnessy JA, Booser DJ, et al. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 2003;21:1007-1014.
147. Munster PN, Buzdar A, Dhingra K, et al. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. J Clin Oncol 2001;19:2002-2009.
148. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-1228.
149. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821-831.
150. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007;22:1832-1841.
151. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone 2008;43:222-229.
152. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24:153-161.
153. Cummings S, Zanchetta J, McClung M, et al. The effects of twice-yearly denosumab on fracture risk in women with osteoporosis. Osteoporos Int 2009;20:516.